###### Strengths and limitations of this study

-   This is a single-centre study that used a cohort of unselected Greek and Romanian patients with colorectal cancer.

-   We developed and validated a new fast and reliable HRM analysis protocol for *KRAS* (exons 2, 3 and 4), *NRAS* (exons 2, 3 and 4) and *BRAF* (exon 15) mutation detection.

-   The mutation frequency of *KRAS*, *NRAS* and *BRAF* was determined for the first time in Greek and Romanian populations.

-   The main limitation of the study was that not all the epidemiological data were collected.

Introduction {#s1}
============

The *RAS* proto-oncogenes (*HRAS*, *KRAS* and *NRAS*) encode a family of highly homologous proteins. They participate in a signal transduction cascade, namely the RAS/RAF/MEK/ERK pathway, which regulates the growth and survival properties of cells. They are controlled by extracellular signals transmitted by the transmembrane receptor tyrosine kinase and epidermal growth factor receptor (EGFR).[@R1]

Two monoclonal antibodies (cetuximab and panitumumab) were designed as effective inhibitors of the EGFR. However, anti-EGFR therapy is not effective in patients harbouring activating mutations in genes of the RAS/RAF/MEK/ERK pathway.[@R2]

In total, activating mutations in the *RAS* genes, mainly in exons 2 and 3 (codons 12/13 and 61), occur in approximately 20% of all human cancers. Mutations in *KRAS* account for about 85% of all *RAS* mutations in human tumours, *NRAS* for about 15% and *HRAS* for less than 1%.[@R1] Acquired mutations in exon 2 of the *KRAS* gene (at codons 12/13) are commonly used to identify patients with colorectal cancer who are unlikely to benefit from anti-EGFR therapy. However, more than half of patients with *KRAS* codons 12/13 wild-type colorectal cancer still fail to respond to anti-EGFR therapy, suggesting the involvement of mutations at other locations of the gene or other genes that act downstream of EGFR in the RAS/RAF/MEK/ERK pathway.[@R3]

Recent studies showed that mutations in exons 3 and 4 of *KRAS*, exons 2, 3 and 4 of the *NRAS* gene and exon 15 of the *BRAF* gene are associated with poor prognosis or resistance to anti-EGFR antibody in metastatic colorectal cancer.[@R4] Additionally, it has been reported that patients harbouring any activating RAS mutations not only do not benefit from but may be harmed by panitumumab--FOLFOX4 treatment.[@R6]

High sensitivity and specificity are pre-requisites when selecting the appropriate method for somatic mutation detection. High-resolution melting (HRM) curve analysis is considered an accurate, fast and sensitive method that can be used for hereditary or somatic mutation screening.[@R8] The HRM melting profile is a specific sequence-related pattern allowing discrimination between wild type sequences and homozygote--heterozygote variants. Since it is a more sensitive approach compared with direct sequencing, it allows the detection of even a minimal fraction of mutated cells.[@R9] This is important when dealing with somatic mutations, where the percentage of mutant alleles in the DNA analysed can be very low in some cases.

The aim of this study was the development and validation of an HRM method for the detection of *KRAS*, *NRAS* and *BRAF* mutations in colorectal patients. Additionally, we aimed to compare for each one of these genes mutation frequency in Greek and Romanian patients with colorectal cancer.

Methods {#s2}
=======

Samples and DNA extraction {#s2a}
--------------------------

A total of 2425 patients with colorectal cancer participated in the study ([figure 1](#BMJOPEN2013004652F1){ref-type="fig"}). In total, 2071 patients with colorectal cancer were analysed for *KRAS* exon 2 mutations. One thousand six hundred ninety nine of them were of Greek origin and 372 of Romanian origin. Additionally, a consecutive series of 354 patients was selected to perform the full *KRAS*, *NRAS* and *BRAF* mutation analysis. The material selected for mutation analysis was formalin-fixed and paraffin-embedded (FFPE) sections from the primary colorectal tumour. Informed consent was obtained from all patients before testing. The study was approved by the ethical committee of 'Agii Anargiri' Cancer Hospital.

![Study workflow, patient distribution and mutation frequencies.](bmjopen2013004652f01){#BMJOPEN2013004652F1}

DNA extraction was performed from a 10 µm thick section of the FFPE tissue sample. Pathological review was obtained for all samples and macrodissection was performed to ensure tumour cell content (TCC) of \>75%, when possible. The tumour area was marked by comparison with the corresponding H&E-stained slide. DNA was extracted using the NucleoSpin Tissue Kit (Macherey-Nagel) according to the manufacturer\'s instructions.

Mutation analysis {#s2b}
-----------------

*KRAS* and *NRAS* exons 2, 3 and 4 and *BRAF* exon 15 mutation analysis was performed using an HRM analysis. PCR cycling and HRM analysis were performed on the Rotor-Gene 6000 (Corbett Research). The intercalating dye used was SYTO 9 (Invitrogen). More specifically, PCR assays were carried out in 25 μL reaction volume containing 100 ng of genomic DNA, 1×PCR buffer, 2.5 mmol/L MgCl~2~, 200 nmol/L of each primer, 200 µmol/L of each dNTP, 5 µmol/L of SYTO 9, 1.25 U of HotStarTaq (QIAGEN Inc., Valencia, CA; 5 U/µL) and PCR grade water.

Primer pairs for *BRAF*, *KRAS* exon 4 and *NRAS* exon 4 were designed with primer-BLAST software (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>). Primer pairs for *KRAS* exons 2 and 3 and *NRAS* exons 2 and 3 were previously described[@R8] [@R10] [@R11] ([table 1](#BMJOPEN2013004652TB1){ref-type="table"}). The PCR conditions were: initial denaturation at 95°C for 15 min, followed by 40 cycles of 15 s at 95°C, 30 s at the annealing temperature and 15 s at 72°C. For the HRM analysis profile, samples were denatured with an initial hold of 95°C for 1 s and a melting profile from 72°C to 95°C rising at 0.2°C. The annealing temperature was 56°C for all amplicons, except for *KRAS* exon 2 for which we used an annealing temperature of 67.5°C. All HRM reactions were run in triplicate.

###### 

Primer sequences and amplicon length of the high-resolution melting experiment

  Primer name   Primer sequence               Genetic region                Fragment length
  ------------- ----------------------------- ----------------------------- -----------------
  KRASF2        TTATAAGGCCTGCTGAAAATGACTGAA   *KRAS* exon 2 (NC_018923.2)   92bp
  KRASR2        TGAATTAGCTGTATCGTCAAGGCACT                                  
  KRAS61F       CCAGACTGTGTTTCTCCCTT          *KRAS* exon 3 (NC_018923.2)   155bp
  KRAS61R       CACAAAGAAAGCCCTCCCCA                                        
  KRASex4f      TGATTTTGCAGAAAACAGAT          *KRAS* exon 4 (NC_018923.2)   120bp
  KRASex4r      GACACAAAACAGGCTCAGGA                                        
  NRASex.2Fw    GGTGTGAAATGACTGAGTAC          *NRAS* exon 2 (NC_018912.2)   128bp
  NRASex.2Rev   GGGCCTCACCTCTATGGTG                                         
  NRASex.3Fw    AAACAAGTGGTTATAGATGGT         *NRAS* exon 3 (NC_018912.2)   97bp
  NRASex.3Rev   CACAGAGGAAGCCTTCGCCT                                        
  NRASex4f      CTTGCACAAATGCTGAAAGC          *NRAS* exon 4 (NC_018912.2)   124bp
  NRASex4r      TTTGCCAACAAGGACAGTTG                                        
  BRAFex15 F    CCTCAATTCTTACCATCC            *BRAF* exon 15 NC_018918.2    119bp
  BRAFex15R     ATGAAGACCTCACAGTAA                                          

Whenever equivocal results between HRM and sequencing were observed in *KRAS* exon 2 amplicon, an alternative mutagenic PCR-RFLP (Restriction Fragment Length Polymorphism) method was used to test for mutations in codons 12/13 of the *KRAS* gene.[@R12]

Sequencing analysis {#s2c}
-------------------

For the Sanger sequencing reaction, PCR amplification products were purified using the NucleoFast 96 PCR Clean-up Kit (Macherey-Nagel), according to the manufacturer\'s protocol. Seven μL of the purified product were used for the sequencing reaction using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems Inc., Fostercity, California, USA). Sequencing reaction products were purified prior to electrophoresis using the Montage SEQ~96~ Sequencing Reaction Kit (Millipore Corporation). Sequencing analysis was performed on an Applied Biosystems 3130 Genetic Analyzer.

Sensitivity {#s2d}
-----------

The sensitivity test was performed using genomic DNA reference standards with defined allelic frequencies (Horizon diagnostics).

*KRAS* G12D, *NRAS* G12D, *NRAS* Q61K and *BRAF* V600E heterozygous DNAs (allele frequency 50%) were diluted with wild-type DNA in order to obtain a mutant to wild-type allelic ratio of 25%, 12.5%, 10%, 7.5% and 5%, respectively.

Statistical analysis {#s2e}
--------------------

Statistical analysis was performed using either Fisher\'s exact or χ^2^ tests. A p value less than 0.05 was considered as the cut-off for statistical significance. Statistical analysis was performed with the MedCalc software V.12.7.2.

Results {#s3}
=======

Sensitivity test {#s3a}
----------------

Using HRM we were able to detect 5% of mutant *KRAS* G12D in wild-type DNA, 5% of mutant *NRAS* G12D allele in wild-type DNA, 7.5% of mutant *BRAF* V600E allele in wild-type DNA and 7.5% of mutant *NRAS* Q61K allele in wild-type DNA ([figure 2](#BMJOPEN2013004652F2){ref-type="fig"}). Using the sequencing method for the same mutations we were able to detect 12% of mutant alleles in wild-type DNA.

![Difference graphs of the sensitivity test. Serial dilutions were performed in order to obtain a mutant to wild-type allele ratio of 50%, 25%, 12.5%, 7.5% and 5%. (A) *NRAS* G12D allele in wild-type DNA. (B) *NRAS* Q61K allele in wild-type DNA. (C) *BRAF* V600E allele in wild-type DNA.](bmjopen2013004652f02){#BMJOPEN2013004652F2}

*KRAS* exon 2 mutation analysis {#s3b}
-------------------------------

*KRAS* exon 2 mutations were detected in 702 of the 1699 Greek patients with colorectal carcinoma (CRC) analysed (41.3%) and in 39.2% (146/372) of the Romanian patients ([figure 1](#BMJOPEN2013004652F1){ref-type="fig"}). There was no statistically significant difference between the two groups (p=0.5). In total, 77.3% of the mutations were detected in codon 12 and 22.7% in codon 13. The most prevalent mutation was c.35G\>A (p.G12D) accounting for 29.48% of all the exon 2 mutations followed by c.38G\>A (p.G13D) and c.35G\>T (p.G12V; 19.36% each; [figure 3](#BMJOPEN2013004652F3){ref-type="fig"}). In three samples no mutation could be detected by sequencing analysis, while HRM showed an abnormal melting profile which is indicative of the presence of a mutation. In these cases an alternative PCR-RFLP method was used.[@R12] The results obtained indicated the presence of a mutation in codon 12 in one case and in codon 13 in the other two cases.

![Distribution of the different mutation types found in *KRAS* exon 2 (codons 12 and 13) patients with mutant colorectal carcinoma. Percentages refer to the group of mutated tumours.](bmjopen2013004652f03){#BMJOPEN2013004652F3}

Full *KRAS*/*NRAS* (exons 2, 3 and 4) mutation analysis {#s3c}
-------------------------------------------------------

DNA from 354 consecutive patients (193 of Greek origin and 161 of Romanian origin) was subjected to *KRAS*/*NRAS* (exons 2, 3 and 4) and *BRAF* (exon 15) analysis. In total, 145 (82 Greek, 63 Romanian) of them were found to carry a mutation in exon 2 of the *KRAS* gene. The combined mutation frequency was 40.96% (42.48% for the Greek population and 39.1% for the Romanian population; [figure 1](#BMJOPEN2013004652F1){ref-type="fig"}).

The remaining 209 (111 Greek, 98 Romanian) exon 2 wild type CRC samples were screened in parallel by HRM and sequencing analysis for mutations in exons 3 and 4 of *KRAS*, exons 2, 3 and 4 of *NRAS* and exon 15 of *BRAF* ([figure 1](#BMJOPEN2013004652F1){ref-type="fig"}). There was a 99% concordance between the two methods. All mutations detected by Sanger sequencing were also detected by HRM.

In two cases an abnormal melting profile was observed by HRM, while no mutation could be detected using sequencing analysis. The first case concerned the *NRAS* exon 2 amplicon and the second the *NRAS* exon 3 amplicon. Since there was not an alternative method to validate the results obtained by the two methods, these samples were excluded from the study.

Automated sequencing of the HRM PCR products confirmed the presence of 32 mutations, with the following distribution: 12 in *KRAS* (4 in exon 3 and 8 in exon 4), 20 in *NRAS* (15 in exon 2, 4 in exon 3 and 1 in exon 4; [table 2](#BMJOPEN2013004652TB2){ref-type="table"}).

###### 

Mutation frequency detected in Greek and Romanian *KRAS* exon 2 wild-type populations

  Population   *KRAS* exon 3   *KRAS* exon 4   *NRAS* exon 2    *NRAS* exon 3   *NRAS* exon 4   *BRAF* exon 15
  ------------ --------------- --------------- ---------------- --------------- --------------- -----------------
  Romanian     2/98 (2.04%)    2/98 (2.04%)    7/98 (7.14%)     2/98 (2.04%)    1/98 (1.02%)    10/98 (10.21%)
  Greek        2/111 (1.80%)   6/111 (5.4%)    8/111 (7.20%)    2/111 (1.80%)   0/111 (0.00%)   16/111 (14.41%)
  Total        4/209 (1.91%)   8/209 (3.82%)   15/209 (7.18%)   4/209 (1.91%)   1/209 (0.48%)   26/209 (12.44%)
  p Value      1               0.3             1                1               0.5             0.5

Thus, in our study 15.31% of wild-type *KRAS* exon 2 (codons 12/13) samples harbour a mutation in *KRAS* exons 3 and 4 and *NRAS* exons 2, 3 and 4 ([figure 4](#BMJOPEN2013004652F4){ref-type="fig"}). This result is comparable with those obtained in other recent studies.[@R3] [@R6] [@R13]

![*KRAS* exons 3 and 4, *NRAS* exons 2, 3 and 4 and *BRAF* exon 15 mutation frequency in 209 KRAS exon 2 wild type patients with colorectal cancer.](bmjopen2013004652f04){#BMJOPEN2013004652F4}

*BRAF* mutation analysis {#s3d}
------------------------

Among the 209 *KRAS* exon 2 wild-type patients tested *BRAF* exon 15 mutations were detected in 26 of them (12.44%; [table 2](#BMJOPEN2013004652TB2){ref-type="table"}). The mutual exclusivity of *KRAS* (exons 3 and 4), *NRAS* (exons 2, 3 and 4) and *BRAF* mutations was confirmed, since none of the patients with a *KRAS*/*NRAS* mutation presented a simultaneous mutation at one of the other *RAS* exons tested or at *BRAF*.

There was no statistically significant difference in the mutation frequency of the genes tested or the mutation distribution between the two populations ([tables 2](#BMJOPEN2013004652TB2){ref-type="table"} and [3](#BMJOPEN2013004652TB3){ref-type="table"}). Among *KRAS* exon 2 wild-type cases only 72.25% (151/209) remained wild type for all regions studied, while 15.31% harboured additional *RAS* mutations and 12.44% *BRAF* mutations. This means that an additional 16.38% of the patients tested (27.75% of the *KRAS* exon 2 normal group) are unlikely to benefit from anti-EGFR therapy, reducing the percentage of patients to be treated from 59.04% to 42.66%.

###### 

Types of RAS/BRAF mutations detected in KRAS exon 2 wild-type Greek and Romanian populations

  ---------------------------------------------------------------------------------
  Gene     Exon   Codon   Mutations                              Romanian   Greek
  -------- ------ ------- -------------------------------------- ---------- -------
  *KRAS*   3      61      c.181C\>A (p.Q61K)\                    2          2
                          p.Q61L (c.182A\>T                                 

  *KRAS*   4      146     c.436G\>A (p.A146T),\                  2          6
                          c.437C\>T (p.A146V)                               

  *NRAS*   2      12      c.35G\>A (p.G12D), c.34G\>T (p.G12C)   7          8

  *NRAS*   3      12      c.181C\>A (p.Q61K)                     2          2

  *NRAS*   4      146     p.A146V (c.437C\>T)                    1          0

  *BRAF*   15     600     c.1799T\>A (p.V600E)                   10         16
  ---------------------------------------------------------------------------------

Discussion {#s4}
==========

Mutation detection in any of the genes involved in the RAS/RAF/MEK/ERK pathway has a great impact on CRC treatment decision and patient management. Thus reliable molecular methods are needed to identify such mutations. HRM analysis is considered a highly specific and sensitive method that is currently widely used in somatic mutation detection.[@R8] [@R14] [@R15]

The HRM analysis we used generated specific melting profiles that allowed the discrimination between wild type and mutated samples ([figure 5](#BMJOPEN2013004652F5){ref-type="fig"}). It was proved to be reliable since all mutations detected by Sanger sequencing were also detected by HRM. Additionally, HRM analysis is much faster and cost effective compared with sequencing analysis. Thus, it can be used as a fast screening method to detect mutant samples. However, further characterisation of the specific mutation requires sequencing analysis.

![Normalised graphs of the high-resolution melting analysis containing wild type and mutant samples. (A) *NRAS* exon 2 amplicon. (B) *NRAS* exon 3 amplicon. (C) *BRAF* exon 15 amplicon.](bmjopen2013004652f05){#BMJOPEN2013004652F5}

The high sensitivity of the method was confirmed in our experiments, since we achieved a sensitivity of mutant/wild-type allele detection that ranged between 5% and 7.5% (depending on the mutation type and amplicon), while sequencing analysis had a sensitivity of 12--15%. It has been reported that HRM is a more sensitive method compared with Sanger sequencing, however, it has also been reported that this method can give some false-positive results due to bad DNA quality, especially when the starting material is FFPE tissue.[@R16] Thus, whenever equivocal results are obtained, an alternative method should be used in order to confirm the presence of a mutation. In our study, three samples were positive for a mutation in *KRAS* exon 2 amplicon by HRM, but were negative by sequencing. For this amplicon an alternative PCR-RFLP approach was used and the results obtained verified the presence of mutations in all three samples. Additionally, two cases that concerned *NRAS* exon 2 and *NRAS* exon 3 amplicons were positive by HRM and negative by sequencing. Since there was no alternative method to validate the results obtained by the two methods these samples were excluded from the study.

Another important factor affecting sensitivity is appropriate tissue selection. We consider the existence of pathological review for all samples crucial. Using macrodissection we ensured a per cent TCC of \>75.

Until recently, analysis of patients with colorectal cancer who would respond to anti-EGFR therapy involved only mutation detection of *KRAS* exon 2, which has a frequency of 40%.[@R17]

Almost all information on the molecular features of human malignancies is derived from European and US patients. There is, however, growing evidence that these findings may not be applicable to all ethnic groups. It has been reported that *KRAS* exon 2 (codons 12/13) mutation percentage in CRC is lower in Asian and Middle Eastern populations (24%) than in European and Latin American populations (36% and 40%, respectively).[@R20] However, even in Asian and Middle Eastern populations there is heterogeneity in mutation rates among different ethnicities.[@R21] It is unclear if this is due to different genetic backgrounds or due to environmental and lifestyle differences between the nations.

In our study *KRAS* exon 2 mutation frequency was 41.3% (702/1699) in Greek patients and 39.2% (146/372) in Romanian patients. These results are similar to those obtained in European populations.[@R20] There was no statistically significant difference between the two populations (p=0.5).

The presence of mutations in codons 12/13 of the *KRAS* gene was believed to be a specific determinant of failure to respond to anti-EGFR therapy. However, there is still quite a significant number (35--50%) of wild-type patients who do not benefit from the treatment.[@R6] [@R13] [@R22] Recently it was shown that additional *KRAS* and *NRAS* mutations occur in a substantial proportion of patients with metastatic colorectal cancer and that they have a predictive value.[@R4] However, data concerning mutation frequency of the *RAS* mutations other than *KRAS* exon 2 are very limited.

In three recent studies (performed by Guedes *et al*,[@R13] Vaughn *et al*[@R3] and Douillard *et al*[@R6]) *KRAS* exons 3 and 4 mutation frequency was investigated in *KRAS* exon 2 wild-type patients (number of patients included: 201, 513 and 641, respectively). In these studies *KRAS* exon 3 mutation frequency ranged between 3.7% and 6.5% (weighted average 4.1%), while that of *KRAS* exon 4 mutations ranged between 3.3% and 6.5% (weighted average 4.9%). In our study the mutation frequency of *KRAS* exons 3 and 4 was found to be 1.9% (4/209) and 3.8% (8/209), respectively (χ^2^=1.8, p=0.2 and χ^2^=0.27, p=0.6, respectively; [table 2](#BMJOPEN2013004652TB2){ref-type="table"}). Additionally, there was no statistically significant difference in the mutation frequency between the two populations.

Even less data exists concerning *NRAS* mutation frequency. Two of the aforementioned studies (performed by Vaughn *et al*,[@R3] and Douillard *et al*[@R6]) also analysed *NRAS* gene in *KRAS* exon 2 wild-type patients.[@R13] Mutation frequency of *NRAS* exon 2 was 1.9% and 3.4% (weighted average 2.77%), while exon 3 was mutated with a percentage of 3.1% and 4% (weighted average 3.64%). In our study the mutation frequency for *NRAS* exon 2 was 7.18% (15/209) which is higher compared with previous studies (χ^2^=9.06, p=0.003), while the mutation frequency of exon 3 does not differ significantly, 1.9% (4/209; χ^2^=1.14, p=0.3).

*NRAS* exon 4 mutation in CRC seems to be a very rare event with a frequency of \<0.2%.[@R23] In our study only one sample was found to carry a mutation in this exon (0.28% of the total patients studied).

Thus, according to recent data 12--17% of wild-type *KRAS* exon 2 (codons 12/13) patients harbour a mutation in *KRAS* exons 3 and 4 and *NRAS* exons 2, 3 and 4.[@R3] [@R6] [@R13] In our study this percentage was 15.31% ([figure 4](#BMJOPEN2013004652F4){ref-type="fig"}).

In our study *BRAF* mutations were present in 12.44% of *KRAS* exon 2 wild-type patients. This result is comparable with the results obtained in other studies.[@R6] [@R23] [@R24] There was no statistically significant difference in the mutation frequency between the two populations analysed ([table 2](#BMJOPEN2013004652TB2){ref-type="table"}).

In 354 consecutive patients with CRC *KRAS* exon 2 mutations were detected in 40.96% of the cases. In the remaining 59.04% exon 2 wild-type patients we detected 15.31% additional *RAS* mutations and 12.44% *BRAF* mutations, reducing the proportion of true wild-type patients from 59.04% to 42.66%. This means that 27.75% of the *KRAS* exon 2 wild-type patients are unlikely to benefit from anti-EGFR treatment ([figure 4](#BMJOPEN2013004652F4){ref-type="fig"}). The selection of patients eligible to receive anti-EGFR treatment helps reduce the costs of unnecessary treatment. This percentage will probably increase with the addition in the mutation analysis of more genes that participate in the signalling pathways controlled by EGFR, such as the *HRAS* gene, which is the third member of the *RAS* family and *PIK3CA* gene that participates in the PI3K-AKT pathway.

Conclusions {#s5}
===========

The HRM method we developed proved to be a cost effective, rapid and sensitive approach for *KRAS*, *NRAS* and *BRAF* mutation screening. To the best of our knowledge this is the first study reporting *KRAS*, *NRAS* and *BRAF* mutation frequency in Greek and/or Romanian patients with colorectal cancer. The *KRAS* exon 2 mutation frequency observed was 41.3% (702/1699) and 39.2% (146/372) in Greek and Romanian patients, respectively. Additionally, our findings indicate that in 209 wild-type *KRAS* exon 2 patients, full *KRAS*, *NRAS* and *BRAF* mutation analysis led to the detection of additional 15.31% patients with colorectal cancer with exon 3 or 4 *KRAS* mutations or with *NRAS* mutations and 12.44% with *BRAF* exon 15 mutations. No difference in the mutation frequency was observed between the Greek and Romanian population. We conclude that more than one-fourth of the *KRAS* exon 2 wild-type patients present with mutations in other genetic positions which confer resistance to anti-EGFR therapy.
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